Related Experiment Video
Updated: May 11, 2026
A Reproducible Cartilage Impact Model to Generate Post-Traumatic Osteoarthritis in the Rabbit
Published on: November 21, 2023
Post-traumatic osteoarthritis: from mouse models to clinical trials
Christopher B Little1, David J Hunter
1Raymond Purves Bone and Joint Research Laboratories, Kolling Institute of Medical Research, Institute of Bone and Joint Research, University of Sydney at Royal North Shore Hospital, St Leonards, NSW 2065, Australia. christopher.little@ sydney.edu.au
Post-traumatic osteoarthritis (PTOA) models in mice show distinct molecular differences from spontaneous osteoarthritis, impacting therapeutic development. This review explores molecular targets for PTOA, focusing on clinical translation challenges.
Area of Science:
- Orthopedics
- Rheumatology
- Molecular Biology
Background:
- Osteoarthritis (OA) is a major cause of disability with significant socioeconomic costs.
- Therapeutic translation for OA has been hindered by discrepancies between preclinical models and human disease.
- Current animal models often mimic post-traumatic OA (PTOA) rather than spontaneous OA.
Purpose of the Study:
- To review molecular targets for PTOA prevention and modification.
- To summarize findings from genetically modified mouse studies.
- To identify challenges in translating PTOA therapies to human clinical trials.
Main Methods:
- Review of studies using genetically modified mice to investigate PTOA pathophysiology.
- Analysis of preclinical therapeutic trial data for PTOA targets.
- Evaluation of translation of findings from animal models to human clinical settings.
Main Results:
- Genetically modified mouse studies reveal distinct molecular pathways in PTOA compared to spontaneous OA.
- Specific molecular targets have shown promise in preclinical PTOA models.
- Differences in disease mechanisms between animal models and human OA contribute to therapeutic translation failures.
Conclusions:
- Understanding PTOA's unique molecular basis is crucial for developing effective disease-modifying therapies.
- Translating preclinical findings for PTOA requires careful consideration of human disease complexity.
- Addressing challenges in clinical trial design is essential for successful PTOA drug development.
